Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
- 28 June 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 21 (12), 1645-1653
- https://doi.org/10.1016/s1473-3099(21)00319-4
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- COVID-19 in children and young peopleScience, 2020
- An Effective COVID-19 Vaccine Needs to Engage T CellsFrontiers in Immunology, 2020
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity OutcomesJAMA, 2020
- Development of an inactivated vaccine candidate for SARS-CoV-2Science, 2020
- Multisystem Inflammatory Syndrome in Children (MIS-C) with COVID-19: Insights from simultaneous familial Kawasaki Disease casesInternational Journal of Infectious Diseases, 2020
- The Importance of Advancing Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in ChildrenClinical Infectious Diseases, 2020
- Coronavirus Infections in Children Including COVID-19The Pediatric Infectious Disease Journal, 2020
- Comparison of the effect of increased hepatitis B vaccine dosage on immunogenicity in healthy children and adultsHuman Vaccines & Immunotherapeutics, 2016
- Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysisHuman Vaccines & Immunotherapeutics, 2015
- Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trialVaccine, 2012